drugset
drugset / Trial / NCT01820091

Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®

NCT01820091 ↗

Phase 1 Withdrawn Acrotech Biopharma Inc.
Non-randomizedParallel-groupOpen-labelPrevention

Summary

To determine the optimal dose and schedule of Fusilev to prevent or reduce Folotyn-related Grade 3 or higher oral mucositis in patients with Non-Small Cell Lung Cancer.

Timeline

Start
2013-04
Primary completion
2015-04
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Levoleucovorin Unknown 5 mg/m2 —
Background Pralatrexate Other / unclassified 190 mg/m2 —

Indications

non-small cell lung carcinoma